“Alzheimer's disease” is neither “Alzheimer's clinical syndrome” nor “dementia”

[1]  W. Jagust,et al.  Relationships Between Tau and Glucose Metabolism Reflect Alzheimer's Disease Pathology in Cognitively Normal Older Adults. , 2019, Cerebral cortex.

[2]  Eric E. Smith,et al.  Vascular dysfunction—The disregarded partner of Alzheimer's disease , 2019, Alzheimer's & Dementia.

[3]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[4]  Dimitrios Kapogiannis,et al.  Magnetic resonance spectroscopy reveals abnormalities of glucose metabolism in the Alzheimer's brain , 2018, Annals of clinical and translational neurology.

[5]  A. Gjedde,et al.  Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment , 2017, Scientific Reports.

[6]  Prashanthi Vemuri,et al.  Age, vascular health, and Alzheimer disease biomarkers in an elderly sample , 2017, Annals of neurology.

[7]  Reisa A. Sperling,et al.  The association between tau PET and retrospective cortical thinning in clinically normal elderly , 2017, NeuroImage.

[8]  A. Rahmim,et al.  Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition , 2017, JAMA.

[9]  Jorge Sepulcre,et al.  Fluorodeoxyglucose metabolism associated with tau‐amyloid interaction predicts memory decline , 2017, Annals of neurology.

[10]  Sterling C. Johnson,et al.  Macrovascular and microvascular cerebral blood flow in adults at risk for Alzheimer's disease , 2017, Alzheimer's & dementia.

[11]  F. Schmitt,et al.  Diabetes is associated with cerebrovascular but not Alzheimer's disease neuropathology , 2016, Alzheimer's & Dementia.

[12]  Gereon R. Fink,et al.  Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease , 2016, Annals of clinical and translational neurology.

[13]  I. Zerr,et al.  Cerebral microbleeds in early Alzheimer’s disease , 2016, Journal of Neurology.

[14]  David A. Bennett,et al.  Relation of Cerebral Vessel Disease to Alzheimer’s Disease Dementia and Cognitive Function in Older Persons: A Cross-sectional Study , 2016, The Lancet Neurology.

[15]  Daniel R. Schonhaut,et al.  Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. , 2016, Brain : a journal of neurology.

[16]  L. Wahlund,et al.  Cerebral Microbleeds: Different Prevalence, Topography, and Risk Factors Depending on Dementia Diagnosis—The Karolinska Imaging Dementia Study , 2015, American Journal of Neuroradiology.

[17]  Arthur W. Toga,et al.  Blood-Brain Barrier Breakdown in the Aging Human Hippocampus , 2015, Neuron.

[18]  C. Jack,et al.  Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly , 2015, Brain : a journal of neurology.

[19]  C. DeCarli,et al.  Associations between serum cholesterol levels and cerebral amyloidosis. , 2014, JAMA neurology.

[20]  Alexander Leemans,et al.  Multiple microbleeds are related to cerebral network disruptions in patients with early Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[21]  J. Trojanowski,et al.  Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. , 2013, Brain : a journal of neurology.

[22]  Denise C. Park,et al.  Risk factors for β-amyloid deposition in healthy aging: vascular and genetic effects. , 2013, JAMA neurology.

[23]  Reisa A. Sperling,et al.  Cognitive Profile of Amyloid Burden and White Matter Hyperintensities in Cognitively Normal Older Adults , 2012, The Journal of Neuroscience.

[24]  Cindee M. Madison,et al.  Cerebrovascular disease, beta-amyloid, and cognition in aging , 2012, Neurobiology of Aging.

[25]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[26]  R. Deane,et al.  Clearance of amyloid-β peptide across the blood-brain barrier: Implication for therapies in Alzheimer’s disease , 2009 .

[27]  R. Deane,et al.  Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. , 2009, CNS & neurological disorders drug targets.

[28]  A. Hofman,et al.  Prevalence and risk factors of cerebral microbleeds , 2008, Neurology.

[29]  D E Kuhl,et al.  Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  H. Fukuyama,et al.  Glucose metabolism and rate constants in Alzheimer's disease examined with dynamic positron emission tomography scan , 1989, Acta neurologica Scandinavica.